Imatinib is superior to IFN+Ara-C treatment with regard to hematological, cytogenetic, and molecular responses (imatinib is the ‘standard of care’ in CML). Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.